SDI Review Form 1.6

Journal Name:	**International Journal of Medical and Pharmaceutical Case Reports**
Manuscript Number:	**Ms_IJMPCR_48191**
Title of the Manuscript:	**CUTANEOUS SIDE EFFECT OF HYDROXUREA IN A SICKLE CELL ANAEMIA CHILD-A CASE REPORT**
Type of the Article	**Case study**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

PART 1: Review Comments

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	When the rashes disappeared following the once in 3days 250mg HU dose, the authors should have demonstrated the effect of this dose and frequency on the haemoglobin profile of the patient. Can we prove this dosage/frequency increased the level of HbF?	She has been on the hydroxyurea continuously for about 10months now without any episode of painful crisis since re-commencement of HU. This is against the period preceding hydroxyurea use. Frequency of bone pain crisis reduced significantly, this is as a result of increased fetal haemoglobin as shown in Table III
Minor REVISION comments	Correct the typographical errors outlined in lines 14, 18, 55, 64, 67, 88, 101, 104	All the typographical errors have been corrected.
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	